Souhaitez-vous accéder aux communiqués récents ?

Transparency Notification from Shareholders Ghent, Belgium – 25 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of...

Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 22 May 2025 Publication of Annual Report 2024 Ghent, Belgium – 22 April 2025 – Sequana Medical NV (Euronext...

CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2026 Rule,...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...

Sequana Medical to Attend the “VFB Happening 2025” in Ghent, Belgium on Saturday, 29 March 2025 Ghent, Belgium – 27 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or...

Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or...

Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial...

Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM Continued support from major...

Transparency Notification from Shareholders Ghent, Belgium – 10 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid...

Transparency Notifications from Shareholders Ghent, Belgium – 3 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid...